Redhill Biopharma Ltd. (NASDAQ:RDHL) Sees Significant Drop in Short Interest

Redhill Biopharma Ltd. (NASDAQ:RDHL) saw a significant drop in short interest in September. As of September 15th, there was short interest totaling 37,800 shares, a drop of 50.6% from the August 31st total of 76,500 shares. Based on an average trading volume of 481,600 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.1% of the company’s stock are sold short. Currently, 1.1% of the company’s stock are sold short. Based on an average trading volume of 481,600 shares, the days-to-cover ratio is currently 0.1 days.

Redhill Biopharma Stock Down 14.4%

Redhill Biopharma stock opened at $1.90 on Friday. The company has a fifty day moving average price of $1.51 and a two-hundred day moving average price of $1.90. Redhill Biopharma has a 12 month low of $1.06 and a 12 month high of $9.00.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Redhill Biopharma in a research report on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Redhill Biopharma currently has a consensus rating of “Sell”.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.